TriangleZanubrutinib (NCT06350318)
Zanubrutinib trial for Follicular Lymphoma (NCT06350318). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with untreated, CD20-positive marginal-zone lymphoma or grade one to three-A follicular lymphoma needing systemic treatment. Localized disease suitable for radiation and aggressive transformation are excluded.
The idea: combine daily zanubrutinib tablets with rituximab infusions or injections. Zanubrutinib blocks BTK growth signaling; rituximab targets CD20 to trigger an immune attack. Rituximab is weekly during the first cycle, then monthly, for up to six cycles. Zanubrutinib can continue for twenty-four cycles. Researchers measure response and safety.
This phase 2 study plans 43 patients. Sameh Gaballa leads Moffitt's recruiting Tampa site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.